Cartesian Therapeutics

Yahoo Finance • 8 days ago

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adr... Full story

Yahoo Finance • 17 days ago

Cartesian rebounds after insider purchase

[$10 Banknote Stacking, Green Up Arrow Rise] spawns * Following a ~54% decline this year, Cartesian Therapeutics (RNAC [https://seekingalpha.com/symbol/RNAC]) shares added nearly 20% on Tuesday after a board member of the cell therapy d... Full story

Yahoo Finance • 18 days ago

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 2 months ago

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of induce... Full story

Yahoo Finance • 2 months ago

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such as zamtocabtagene autoleucel (Miltenyi... Full story

Yahoo Finance • 4 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management ex... Full story

Yahoo Finance • 5 months ago

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients. MG... Full story

Yahoo Finance • 6 months ago

Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating

Investing.com - Wedbush initiated coverage on Cartesian Therapeutics (NASDAQ:RNAC) with an Outperform rating and a price target of $38.00 on Wednesday. According to InvestingPro data, analysts maintain a strong buy consensus with price tar... Full story

Yahoo Finance • 7 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the... Full story

Yahoo Finance • 9 months ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its manag... Full story

Yahoo Finance • 10 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announc... Full story

Yahoo Finance • 11 months ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has recei... Full story

Yahoo Finance • 2 years ago

Insiders Are Buying These 11 Penny Stocks

In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024... Full story